Dapoxetine Pills Treat PE In Men 18–64 Years Old

Dapoxetine first compound developed by Eli Lilly for the treatment of premature ejaculation (PE) in men 18–64 years old. It belongs to a class of drug called as selective serotonin re-uptake inhibitor (SSRI)

At present, dapoxetine is licensed in ten countries, including several countries in Europe, and Mexico, South Korea, and New Zealand. PE is the most common sexual dysfunction in men, with a global prevalence estimated to be between 20% and 40%.

PE is characterized by ejaculation prior to, or soon after, vaginal penetration with minimal stimulation, with the male having no control over ejaculation.

Prior to the availability of dapoxetine, psychotherapy (eg, cognitive behavior therapy) was widely used to treat PE. More recently, several SSRIs (other than dapoxetine) have been used off-label to treat PE .These SSRIs were not developed to treat PE, in contrast with dapoxetine which was specifically developed for this purpose and has a different pharmacological profile to the other SSRIs, with properties making it suitable for on-demand dosing.

 Dapoxetine is contraindicated in men with moderate to severe hepatic impairment and in those receiving concomitant therapy with potent cytochrome P450 3A4 inhibitors (eg, ketoconazole, ritonavir, telithromycin), thioridazine, monoamine oxidase inhibitors, serotonin reuptake inhibitors (eg, SSRIs, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants) or other medicinal/herbal products with serotonergic effects (eg, hypericum [St John’s wort]). Dapoxetine is not recommended in men with severe renal impairment, and caution is advised in men with mild to moderate renal impairment. Alcohol and recreational drugs should be avoided when taking dapoxetine.